Tim Anderson
Stock Analyst at B of A Securities
(4.38)
# 519
Out of 5,112 analysts
49
Total ratings
70.37%
Success rate
13.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $204 → $220 | $208.29 | +5.62% | 9 | Dec 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,286 → $1,268 | $1,069.70 | +18.54% | 2 | Dec 15, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $105 → $120 | $100.24 | +19.71% | 5 | Dec 15, 2025 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $52 → $61 | $53.52 | +13.98% | 2 | Dec 15, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $746.13 | -15.97% | 3 | Oct 29, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $25.03 | +19.88% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $325.44 | -16.42% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $77.70 | +11.97% | 1 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $13.43 | +86.15% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $224.61 | -9.18% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $116 → $126 | $121.54 | +3.67% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $41 → $34 | $32.12 | +5.85% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $171.09 | +4.04% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $135.38 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $90.86 | - | 1 | Sep 22, 2017 |
Johnson & Johnson
Dec 15, 2025
Maintains: Neutral
Price Target: $204 → $220
Current: $208.29
Upside: +5.62%
Eli Lilly and Company
Dec 15, 2025
Maintains: Buy
Price Target: $1,286 → $1,268
Current: $1,069.70
Upside: +18.54%
Merck & Co.
Dec 15, 2025
Maintains: Buy
Price Target: $105 → $120
Current: $100.24
Upside: +19.71%
Bristol-Myers Squibb Company
Dec 15, 2025
Upgrades: Buy
Price Target: $52 → $61
Current: $53.52
Upside: +13.98%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $746.13
Upside: -15.97%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $25.03
Upside: +19.88%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $325.44
Upside: -16.42%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $77.70
Upside: +11.97%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $13.43
Upside: +86.15%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $224.61
Upside: -9.18%
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $121.54
Upside: +3.67%
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $32.12
Upside: +5.85%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $171.09
Upside: +4.04%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $135.38
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $90.86
Upside: -